Table of Content - Central Nervous System Disorders Therapeutics Market

Central nervous system (CNS) disorders are some of the most prevalent yet poorly treated illnesses. Achieving sufficient blood-brain barrier (BBB) penetration is one of the biggest challenges in the development of therapeutics for CNS disorders. For instance, according to an article published by National Center for Biotechnology Information, in January 2005, more than 98% of small molecular drugs and almost 100% of larger molecular drugs are ineffective in treating CNS diseases considering that BBB strictly limits the delivery of therapeutic agents to their target site in the CNS. BBB helps to keep homeostasis in the cerebral microenvironment by controlling exchanges of substances between the CNS and the blood and serves an important function in preventing macromolecules, infectious substances, and potential neurotoxins from entering the brain. CNS disorders are rising due to factors such as aging, stress, and, lifestyle changes.

A limited understanding of the pathophysiology underlies that most of the psychiatric disorders such as schizophrenia, major depressive disorder, or bipolar disorder are only effective in a limited proportion of the patients. Some of the CNS disorders include neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease along with various infectious diseases, psychiatric disorders, mental disorders, trauma, mood disorders, and others.

Market Dynamics

The key players are focusing on various growth strategies such as collaborations and agreements which is expected to drive the market growth during the forecast period. For instance, in July 2021, Eli Lilly and Company, an American pharmaceutical company and Banner Alzheimer's Institute announced a strategic research collaboration as part of the planned Phase 3, randomized, placebo-controlled study evaluating donanemab, a biological drug in trial to treat early symptoms of Alzheimer's disease in participants at risk for cognitive and functional decline related to Alzheimer's disease (TRAILBLAZER-ALZ 3). TRAILBLAZER-ALZ 3 will evaluate whether treatment with donanemab can slow the clinical progression of Alzheimer's disease in trial participants.

Key features of the study:

This report provides an in-depth analysis of the global central nervous system disorders therapeutics market , and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global central nervous system disorders therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Biogen Inc., Pfizer Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, AbbVie Inc., Glaxosmithkline plc., Otsuka Pharmaceutical Co., Ltd., Dr. Reddy's Laboratories Ltd., Cipla Inc., Lupin Ltd, and Glenmark Pharmaceuticals
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global central nervous system disorders therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global central nervous system disorders therapeutics market

Detailed Segmentation:

Global central nervous system disorders therapeutics market, By Disease Type:
- Neurodegenerative Disorders
  - Alzheimer’s Disease
  - Parkinson’s Disease
  - Multiple Sclerosis
  - Others
- Infectious Diseases
- Psychiatric Disorders
- Anxiety Disorders
- Trauma
- Mood Disorders
- Others
Global Central Nervous System Disorders Therapeutics Market, By Drug Class:
- Analgesics
- Anti-cholinergic Agents
- Anticonvulsants
- Sedatives and Hypnotics
- Antidepressants
- Antipsychotics
- Others
Global Central Nervous System Disorders Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Central Nervous System Disorders Therapeutics Market, By Region:
- North America
  - By Disease Type
    - Neurodegenerative Disorders
      - Alzheimer’s Disease
      - Parkinson’s Disease
      - Multiple Sclerosis
      - Others
    - Infectious Diseases
    - Psychiatric Disorders
    - Anxiety Disorders
    - Trauma
    - Mood Disorders
    - Others
  - By Drug Class
    - Analgesics
    - Anti-cholinergic Agents
    - Anticonvulsants
    - Sedatives and Hypnotics
    - Antidepressants
    - Antipsychotics
    - Others
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Disease Type
    - Neurodegenerative Disorders
      - Alzheimer’s Disease
      - Parkinson’s Disease
      - Multiple Sclerosis
      - Others
    - Infectious Diseases
    - Psychiatric Disorders
    - Anxiety Disorders
    - Trauma
    - Mood Disorders
    - Others
  - By Drug Class
    - Analgesics
    - Anti-cholinergic Agents
    - Anticonvulsants
    - Sedatives and Hypnotics
    - Antidepressants
    - Antipsychotics
    - Others
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Disease Type
    - Neurodegenerative Disorders
      - Alzheimer’s Disease
      - Parkinson’s Disease
      - Multiple Sclerosis
      - Others
    - Infectious Diseases
    - Psychiatric Disorders
    - Anxiety Disorders
    - Trauma
    - Mood Disorders
    - Others
  - By Drug Class
    - Analgesics
    - Anti-cholinergic Agents
    - Anticonvulsants
    - Sedatives and Hypnotics
    - Antidepressants
    - Antipsychotics
    - Others
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Disease Type
    - Neurodegenerative Disorders
      - Alzheimer’s Disease
      - Parkinson’s Disease
      - Multiple Sclerosis
      - Others
    - Infectious Diseases
    - Psychiatric Disorders
    - Anxiety Disorders
    - Trauma
    - Mood Disorders
    - Others
  - By Drug Class
    - Analgesics
    - Anti-cholinergic Agents
    - Anticonvulsants
    - Sedatives and Hypnotics
    - Antidepressants
    - Antipsychotics
    - Others
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Disease Type
    - Neurodegenerative Disorders
      - Alzheimer’s Disease
      - Parkinson’s Disease
      - Multiple Sclerosis
      - Others
    - Infectious Diseases
    - Psychiatric Disorders
    - Anxiety Disorders
    - Trauma
    - Mood Disorders
    - Others
  - Drug Class
    - Analgesics
    - Anti-cholinergic Agents
    - Anticonvulsants
    - Sedatives and Hypnotics
    - Antidepressants
    - Antipsychotics
    - Others
  - Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - Disease Type
    - Neurodegenerative Disorders
      - Alzheimer’s Disease
      - Parkinson’s Disease
      - Multiple Sclerosis
      - Others
    - Infectious Diseases
    - Psychiatric Disorders
    - Anxiety Disorders
    - Trauma
    - Mood Disorders
    - Others
  - Drug Class
    - Analgesics
    - Anti-cholinergic Agents
    - Anticonvulsants
    - Sedatives and Hypnotics
    - Antidepressants
    - Antipsychotics
    - Others
  - Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Region/Country
    - South Africa
    - Central Africa
    - North Africa
Company Profiles
- Biogen Inc.
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Pfizer Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Novartis AG
- AstraZeneca Plc.
- Teva Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.
- Glaxosmithkline plc.
- Otsuka Pharmaceutical Co., Ltd.
- Reddy's Laboratories Ltd.
- Cipla Inc.
- Lupin Ltd
- Glenmark Pharmaceuticals

“*” marked represents similar segmentation in other categories in the respective section.

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snapshot, By Disease Type
  - Market Snapshot, By Drug Class
  - Market Snapshot, By Distribution Channel
  - Market Snapshot, By Region
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Opportunity
- Impact Analysis
- PEST Analysis
- Regulatory Scenario
- Market Trends
- Key Developments
- Pipeline Analysis
- Regulatory Scenario
- Epidemiology
- Prescription Pattern and Prescribing Behavior
Global Central Nervous System Disorders Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic
- Demand and Supply Analysis
- Epidemiology
- Government Initiatives
Global Central Nervous System Disorders Therapeutics Market, By Disease Type, 2017 – 2028, (US$ Mn)
- Introduction
  - Market Share Analysis, 2021 and 2028 (%)
  - Y-o-Y Growth Analysis, 2018 – 2028
  - Segment Trends
- Neurodegenerative Disorders
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    - Alzheimer’s Disease
    - Parkinson’s Disease
    - Multiple Sclerosis
    - Others
- Infectious Diseases
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Psychiatric Disorders
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Anxiety Disorders
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    - Dry
    - Wet
- Trauma
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Mood Disorders
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
Global Central Nervous System Disorders Therapeutics Market, By Drug Class, 2017 – 2028, (US$ Mn)
- Introduction
  - Market Share Analysis, 2021 and 2028 (%)
  - Y-o-Y Growth Analysis, 2018 – 2028
  - Segment Trends
- Analgesics
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Anti-cholinergic Agents
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Anticonvulsants
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Sedatives and Hypnotics
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Antidepressants
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Antipsychotics
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
Global Central Nervous System Disorders Therapeutics Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Introduction
  - Market Share Analysis, 2021 and 2028 (%)
  - Y-o-Y Growth Analysis, 2018 – 2028
  - Segment Trends
- Hospital Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Retail Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Online Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
Global Central Nervous System Disorders Therapeutics Market, By Region, 2017 – 2028, (US$ Mn)
- Introduction
  - Market Share Analysis, By Region, 2021 and 2028 (%)
  - Y-o-Y Growth Analysis, For Regions, 2017–2028
  - Regional Trends
- North America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
    - U.S.
    - Canada
- Latin America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
    - U.K.
    - Germany
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Region/Country, 2017 – 2028, (US$ Mn)
    - North Africa
    - Central Africa
    - South Africa
Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
  - Biogen Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Pfizer Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Eli Lilly and Company
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Merck & Co., Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Novartis AG
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - AstraZeneca Plc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Teva Pharmaceutical Industries Ltd.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Takeda Pharmaceutical Company Limited
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - AbbVie Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Glaxosmithkline plc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Otsuka Pharmaceutical Co., Ltd.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Reddy's Laboratories Ltd.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Cipla Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Lupin Ltd
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Glenmark Pharmaceuticals
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
- Analyst Views
Section
- Research Methodology
- About us

*Browse 36 market data tables and 43 figures on "Central Nervous System Disorders Therapeutics Market” - Global forecast to 2028

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

Table of Contents

Need a Custom Report?

EXISTING CLIENTELE